Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · IEX Real-Time Price · USD
2.500
0.00 (0.00%)
Apr 25, 2024, 12:06 PM EDT - Market open
Company Description
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.
The company is headquartered in Los Angeles, California.
Armata Pharmaceuticals, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Dr. Deborah L. Birx M.D. |
Contact Details
Address: 5005 Mcconnell Ave Los Angeles, California 90066 United States | |
| Phone | 310-665-2928 |
| Website | armatapharma.com |
Stock Details
| Ticker Symbol | ARMP |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000921114 |
| CUSIP Number | 04216R102 |
| ISIN Number | US04216R1023 |
| Employer ID | 91-1549568 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mina Pastagia M.D., MS | Chief Medical Officer |
| Dr. Deborah L. Birx M.D. | Chief Executive Officer and Director |
| Richard Rychlik | Vice President, Corporate Controller and Principal Financial Officer |
| Peter Hubbard | Vice President of Operations |
| Dr. Pierre Kyme Ph.D. | Senior Vice President of Business and Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 22, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 4, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 4, 2024 | 8-K | Current Report |
| Jan 23, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 15, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 14, 2023 | 10-Q | Quarterly Report |
| Nov 14, 2023 | 8-K | Current Report |
| Sep 20, 2023 | 8-K | Current Report |